5 terminated, 4 recruiting, 2 completed, 1 enrolling by invitation. 11 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Terminated 5, Recruiting 4, Completed 2 |
| Phase 2 | 5 | Recruiting 3, Completed 1, Terminated 1 |
Follow CRISPR Therapeutics AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension CTX340, Placebo - Hypertension | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 69 | 2026-08-08 | 2026-08-11 |
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 60 | 2026-07-17 | 2026-10-20 |
| A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias CTX310 - Cardiovascular, Metabolic Disease | Phase 1 | Recruiting | CRISPR Therapeutics AG | 90 | 2024-06-21 | 2026-09-18 |
| A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies Non Interventional - Hematologic Malignancy, Solid Malignancy | Enrolling by invitation | CRISPR Therapeutics AG | 70 | 2023-11-22 | 2026-09-24 | |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors CTX131 - Clear Cell Renal Cell Carcinoma, Cervical Carcinoma | Phase 1 / Phase 2 | Completed | CRISPR Therapeutics AG | 19 | 2023-03-13 | 2025-11-26 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies CTX112 - B-cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 120 | 2023-03-10 | 2025-11-14 |
| An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D VCTX211 - Diabetes Mellitus, Diabetes Mellitus, Type 1 | Phase 1 | Terminated | CRISPR Therapeutics AG | 5 | 2023-01-20 | 2026-05-07 |
| An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D VCTX210A unit - Diabetes Mellitus, Diabetes Mellitus, Type 1 | Phase 1 | Completed | CRISPR Therapeutics AG | 7 | 2022-01-24 | 2023-06-26 |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) CTX130 - T Cell Lymphoma | Phase 1 | Terminated | CRISPR Therapeutics AG | 49 | 2020-07-31 | 2025-01-08 |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) CTX130 - Renal Cell Carcinoma | Phase 1 | Terminated | CRISPR Therapeutics AG | 19 | 2020-06-16 | 2025-01-08 |
| A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma CTX120 - Multiple Myeloma | Phase 1 | Terminated | CRISPR Therapeutics AG | 26 | 2020-01-22 | 2025-01-08 |
| A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) CTX110 - B-cell Malignancy, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | CRISPR Therapeutics AG | 93 | 2019-07-22 | 2025-10-24 |
Lymphoma (3) · Metabolic Diseases (3) · Autoimmune Diseases (2) · Carcinoma, Renal Cell (2) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 1 (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Immune System Diseases (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Burkitt Lymphoma (1) · Carcinoma (1) · Dyslipidemias (1) · Esophageal Neoplasms (1)
United States (10) · Australia (8) · Canada (7) · Germany (3) · Spain (3) · France (1) · Netherlands (1) · New Zealand (1) · United Kingdom (1)
Annie Weaver, PhD (2) · Manasi Jaiman, MD, MPH (2) · Sandeep Soni, MD (2) · Alissa Keegan, MD (1) · Alissa Keegan, PhD (1) · Melanie Allen, M.Sc. (1)
PMID 37093350, PMID 42023429, PMID 33792221, PMID 37528526, PMID 39617017, PMID 42085626